title: [Lyme disease vaccine: hopes and concerns].
abstract: The vaccine against Lyme disease for last decade became an important issue for many researchers. Recently two groups of scientists published data of their trials carried out on humans. The vaccine which was given to volunteers consisted of recombinant outer surface protein (Osp)A. These people were observed for two years when approximately 79% of them developed resistance to Borrelia burgdorferi infection. These data were evaluated by FDA experts who recommended vaccine for approval. Main concerns of experts are: short duration of observation of vaccinated people, no possibility to vaccinate children, problematic vaccination people with undiagnosed Lyme disease. However the moment when effective and safe vaccine against Lyme disease will be available seems to approach.
authors.affiliation: Kliniki Chorób Pasozytniczych i Neuroinfekcji AM w Białymstoku.
authors.forename: M
authors.initials: M
authors.lastname: Kondrusik
authors.forename: J
authors.initials: J
authors.lastname: Zajkowska
authors.forename: S
authors.initials: S
authors.lastname: Pancewicz
authors.forename: T
authors.initials: T
authors.lastname: Hermanowska-Szpakowicz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001428:Bacterial Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D015748:Borrelia burgdorferi Group / Q000276:immunology*; D005260:Female; D006801:Humans; D008193:Lyme Disease / Q000276:immunology* / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011314:Preventive Health Services / Q000592:standards* / Q000639:trends*; D012189:Retrospective Studies; D014481:United States; D014614:Vaccines, Synthetic / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D001428:Bacterial Vaccines; D014614:Vaccines, Synthetic